What's Behind ARCH Venture Management's Reduced Stake in Maze Therapeutics

Related Articles

What Does BlackRock's Reduced Stake in Orion Corporation Signify

3 months ago

What's Driving the Surge in Analyst Confidence for Venture Global (VG)

5 months ago

What's Behind Acadian Asset Management's Recent Surge

5 months ago

What Does Senator Hagerty's Venture Capital Investment Signal

5 months ago

Category

You may also like

Stock News•1 week ago

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics CMO Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026, equal to 100% of his directly held common stock before the filing.

MAZE

Share

Stock News•3 weeks ago

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics advanced MZE782 for PKU and MZE829 for APOL1 kidney disease; MZE782 showed best-in-class Phase 1 profile with Phase 2 set for mid-2026, while MZE829 posted strong uACR reductions but...

MAZE

Share

Stock News•2 months ago

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study

AstraZeneca shares fell after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising doubts about its expansion into a larger market.

AZN

Share